Application No.: 09/523,776

2

Docket No.: 49632(71699)

## AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions of claims in the application.

Claims 1-44. (cancelled)

Claim 45. (previously presented) A method for treating a mammal suffering from cystic fibrosis, comprising:

administering to the mammal a therapeutically effective amount of at least one compound of the following Formula I:

wherein each W comprises an unsaturated straight carbon chain and is independently optionally substituted alkylene; optionally substituted alkenylene; optionally substituted heteroalkylene; optionally substituted heteroalkylene; optionally substituted heteroalkynynylene;

each Y is independently a carboxy acid, ester, sulfonic acid, nitro, cyano or haloalkyl;

each R is independently halogen, cyano, nitro, optionally substituted alkyl; optionally substituted alkenyl; optionally substituted alkoxy; optionally substituted alkylthio; optionally substituted alkylsulfinyl; optionally substituted alkylsulfonyl; optionally substituted carbocyclic aryl; optionally substituted aralkyl;

m is an integer of from 1 to 6; n is an integer of from 0 to 5; and pharmaceutically acceptable salts thereof,

wherein the compound comprises a straight carbon chain of four carbon atoms, and with the exclusion of 4-phenylbutyric acid.

Application No.: 09/523,776

3

Docket No.: 49632(71699)

Claim 46. (previously presented) The method of claim 45 wherein the compound comprises a carbon-carbon double bond in the second ( $\Delta 2$ ) or third ( $\Delta 3$ ) position of the chain.

- Claim 47. (previously presented) The method of claim 45 wherein the compound further comprises a phenyl ring in the fourth position of the chain.
- Claim 48. (previously presented) The method of claim 45 wherein the compound is 4-phenyl-  $\Delta 3$ -transbutenoic acid or a pharmaceutically acceptable salt thereof.
- Claim 49. (previously presented) The method of claim 45 wherein the compound is 4-phenyl-  $\Delta 2$ -transbutenoic acid or a pharmaceutically acceptable salt thereof.
- Claim 50. (previously presented) The method of claim 45, wherein the compound is 4-phenyl-  $\Delta 3$ -transbutenoate or 4-phenyl-  $\Delta 2$ -transbutenoate.
- Claim 51. (previously presented) The method of claim 45 wherein the mammal is identified as suffering from cystic fibrosis and the compound is administered to the identified mammal.
- Claim 52. (previously presented) The method of claim 48 wherein the mammal is identified as suffering from cystic fibrosis and the compound is administered to the identified mammal.
- Claim 53. (previously presented) The method of claim 49 wherein the mammal is identified as suffering from cystic fibrosis and the compound is administered to the identified mammal.

Application No.: 09/523,776

4

Docket No.: 49632(71699)

Claim 54. (previously presented) The method of claim 50 wherein the mammal is identified as suffering from cystic fibrosis and the compound is administered to the identified mammal.